BPC-157 & TB-500: Joint, Tendon and Spinal Research

BPC-157, a stable gastric pentadecapeptide, and TB-500, a synthetic form of the actin-binding peptide thymosin β4, have both been examined in connective-tissue and musculoskeletal injury models because of reported observations relating to tendon, ligament, bone and neural tissue repair. Research interest in these compounds has centred on whether they influence the organisation and recovery of soft and hard tissue after experimental injury. All studies discussed below are preclinical animal-model or in-vitro work, and Neovia supplies these compounds strictly for in-vitro laboratory research, not for administration to animals or people.

Staresinic et al. (2003) used a rat Achilles-tendon transection model with a parallel in-vitro tendocyte culture and reported accelerated tendon healing in vivo and stimulated tendocyte growth in vitro versus controls. Krivic et al. (2006), working with a rat Achilles tendon-to-bone detachment model, reported promoted tendon-to-bone healing and counteraction of corticosteroid-aggravated healing versus controls. In a related rat Achilles tendon-to-bone transection model, Krivic et al. (2008) reported improved early functional recovery of the tendon-to-bone unit with BPC 157, contrasting with methylprednisolone.

Cerovecki et al. (2010) examined a rat medial collateral ligament transection model and reported functional, biomechanical, macroscopic and histological improvement in ligament healing over 90 days versus controls. In an in-vitro rat Achilles tendon explant and tendon fibroblast model, Chang et al. (2011) reported that BPC 157 accelerated tendon-explant outgrowth and increased fibroblast survival and migration.

Sebecic et al. (1999) used a rabbit segmental radius bone-defect model and reported improved osteogenic healing of the defect with BPC-157, comparable to bone marrow or autologous cortical bone implantation. Novinscak et al. (2008), using a rat gastrocnemius muscle crush-injury model, reported accelerated post-injury muscle healing macroscopically, microscopically, functionally and by serum enzyme activity versus controls.

Dedicated rat-knee-osteoarthritis primary studies were not among the reviewed literature, so the joint-area evidence summarised here is adjacent work in bone and ligament tissue rather than direct osteoarthritis observations.

Ehrlich and Hazard (2010) used a rat subcutaneous sponge-implant granulation-tissue model of connective tissue repair and reported more organised, thicker collagen fibre bundles and a near-absence of myofibroblasts in thymosin beta-4-treated implants versus controls. Xu et al. (2013), in a rat medial collateral ligament injury model, reported that thymosin beta-4 (1 µg in fibrin sealant placed in the ligament gap) was associated with significantly higher biomechanical properties and more uniform collagen fibre organisation at 4 weeks versus controls.

For BPC-157, Gjurasin et al. (2010) used a rat transected sciatic nerve model and reported faster and more homogeneous axonal regeneration, improved electrophysiology and walking, and absence of autotomy versus controls. Perovic et al. (2019) examined a rat sacrocaudal spinal cord compression-injury model and, with a single intraperitoneal injection 10 min post-injury, reported improved motor function, resolved spasticity by day 15, and counteraction of microscopic spinal-cord damage.

For TB-500, Tapp et al. (2009) used an in-vitro human intervertebral disc annulus cell model and reported a significant reduction in disc-cell apoptosis after thymosin beta-4 treatment. Wang et al. (2015), in an in-vitro human intervertebral disc nucleus pulposus cell model with AAV-delivered thymosin beta-4, reported reduced apoptosis and senescence and increased proliferation of nucleus pulposus cells versus controls. Cheng et al. (2014) used a rat spinal cord injury model with intraperitoneal thymosin beta-4 dosing post-injury and reported improved functional and histological outcomes versus saline controls.

These findings come from animal models and in-vitro systems and have not been established in controlled human or veterinary clinical trials. None of the above is dosing, administration, or therapeutic guidance. Neovia Peptides supplies these compounds strictly for in-vitro laboratory research and not for human or veterinary use. See our research disclaimer for full terms.